



GEDEON RICHTER

Richter and Adalvo Sign Global Co-Development Agreement for Semaglutide Injection

Budapest, 6 May 2025 – Gedeon Richter Plc. (“Richter”) and Adalvo Ltd. (“Adalvo”) – a leading B2B pharmaceutical company, developing a pipeline of high-quality generic products – announced today entering into a strategic co-development and license agreement for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management.

This collaboration is built on a shared vision: to shape the future of obesity treatment by ensuring broad access to high-quality alternatives in one of the world’s fastest-growing therapeutic areas. The agreement covers global rights, with both companies sharing development costs and net profits across each other’s markets.

As part of the agreement, Richter is entitled to use the CMO supply chain selected within the framework of the agreement to manufacture the product. However, under certain conditions, Richter also reserves the right to manufacture it in its own facilities for direct commercialization.

“We are pleased to announce this new strategic partnership with Adalvo. Great collaborations are based on synergistic competencies and the relentless attitude to serve our patients competitively. We believe that we share these values with Adalvo and together we can build a global reach to serve patients living with obesity worldwide.” said Bence Kovács, Global Head of General Medicines at Richter.

“This collaboration reflects our strategic ambition to lead market formation in the global obesity space. By joining forces with Gedeon Richter, we are accelerating access to a high-impact GLP-1 therapy and shaping the future of weight management treatments worldwide” said Anil Okay CEO of Adalvo.

Adalvo was the first to bring this opportunity to market and remains committed to driving market formation globally through strategic partnerships. With this collaboration, Gedeon Richter and Adalvo are well-positioned to meet the rising demand for effective weight-management solutions.

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at <http://www.gedeonrichter.com>

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944
EU Community VAT Identification No: HU 10484878 • Internet: www.gedeonrichter.com

About Adalvo

Adalvo is a global pharmaceutical company and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company's declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners. With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That's why our approach is unique, customized to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help our partners reach their goals, be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all its endeavors, driven by a deep-rooted passion for making a difference for partners. The company's purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.

For further information:

Investors: Róbert Réthy, CFA
Media: Zsuzsa Beke

+36 20 342 2555
+36 20 916 4507

